FDA approves simplified use of bivalent COVID vaccines and additional booster for high-risk individuals.
TL;DR Summary
The FDA has authorized changes to the emergency use authorizations of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. Available data show that almost all of the U.S. population 5 years of age and older now have antibodies as a result of either vaccination or infection against SARS-CoV-2. The use of bivalent COVID-19 vaccines for all doses administered to individuals 6 months of age and older is supported by the data.
- Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines FDA.gov
- FDA okays second omicron booster for people at high risk from covid The Washington Post
- Single Dose of Omicron-Targeting Vaccines to Become Main Covid-19 Shot in U.S. The Wall Street Journal
- FDA: Single dose of bivalent COVID vaccine enough for most people The Hill
- F.D.A. Authorizes Another Covid Booster Shot for People Over 65 The New York Times
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
6 min
vs 7 min read
Condensed
93%
1,350 → 96 words
Want the full story? Read the original article
Read on FDA.gov